Published in Vaccine on July 04, 2003
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol (2006) 2.20
Pneumonia research to reduce childhood mortality in the developing world. J Clin Invest (2008) 2.01
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol (2006) 2.00
Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med (2005) 1.97
Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines (2012) 1.69
A threshold method for immunological correlates of protection. BMC Med Res Methodol (2013) 1.41
Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin Diagn Lab Immunol (2005) 1.40
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol (2006) 1.30
Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol (2005) 1.28
Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol (2009) 1.25
Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum. Clin Vaccine Immunol (2009) 1.24
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med (2014) 1.21
New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol (2013) 1.16
Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin Vaccine Immunol (2007) 1.16
Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin Diagn Lab Immunol (2004) 1.15
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J (2014) 1.12
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine (2009) 1.10
Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol (2010) 1.09
Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One (2013) 1.07
Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol (2012) 1.07
Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J (2010) 1.05
Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother (2013) 1.03
Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C. Clin Diagn Lab Immunol (2005) 1.01
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun (2007) 1.01
Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis. MBio (2016) 1.01
Multilaboratory comparison of Streptococcus pneumoniae opsonophagocytic killing assays and their level of agreement for the determination of functional antibody activity in human reference sera. Clin Vaccine Immunol (2010) 0.99
Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol (2010) 0.98
Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis (2011) 0.98
RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect Immun (2011) 0.96
Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol (2005) 0.96
Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol (2014) 0.95
Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clin Vaccine Immunol (2006) 0.94
Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging Dis (2011) 0.93
Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother (2012) 0.93
Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol (2011) 0.93
Measurement and interpretation of pneumococcal IgG levels for clinical management. Clin Exp Immunol (2003) 0.92
Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol (2005) 0.91
Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. Clin Microbiol Infect (2013) 0.90
Comparison of a new multiplex binding assay versus the enzyme-linked immunosorbent assay for measurement of serotype-specific pneumococcal capsular polysaccharide IgG. Clin Vaccine Immunol (2011) 0.89
The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J (2014) 0.88
Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother (2014) 0.87
Development and characterization of a multiplex bead-based immunoassay to quantify pneumococcal capsular polysaccharide-specific antibodies. Clin Vaccine Immunol (2012) 0.87
Anti-pneumococcal antibody titre measurement: what useful information does it yield? J Clin Pathol (2006) 0.86
Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol (2005) 0.83
A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine (2013) 0.83
Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody. MBio (2016) 0.82
Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children. J Immunol Res (2015) 0.81
Changes in B cell immunophenotype in common variable immunodeficiency: cause or effect - is bronchiectasis indicative of undiagnosed immunodeficiency? Clin Exp Immunol (2013) 0.81
Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial. BMC Infect Dis (2005) 0.80
Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads. Vaccine (2010) 0.80
Multilaboratory assessment of threshold versus fold-change algorithms for minimizing analytical variability in multiplexed pneumococcal IgG measurements. Clin Vaccine Immunol (2014) 0.80
Antibody response to a T-cell-independent antigen is preserved after splenic artery embolization for trauma. Clin Vaccine Immunol (2014) 0.79
Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines. Hum Vaccin Immunother (2015) 0.78
Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. PLoS One (2013) 0.77
Some extensions in continuous models for immunological correlates of protection. BMC Med Res Methodol (2015) 0.77
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers. Clin Exp Immunol (2015) 0.77
The Saudi Thoracic Society pneumococcal vaccination guidelines-2016. Ann Thorac Med (2016) 0.76
ASSIGNMENT OF OPSONIC VALUES TO PNEUMOCOCCAL REFERENCE SERUM 007SP FOR USE IN OPSONOPHAGOCYTIC ASSAYS FOR 13 SEROTYPES. Clin Vaccine Immunol (2016) 0.75
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis (2014) 0.75
Seroprevalence of Antibody-Mediated, Complement-Dependent Opsonophagocytic Activity against Neisseria meningitidis Serogroup B in England. Clin Vaccine Immunol (2015) 0.75
Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D. Medicine (Baltimore) (2016) 0.75
Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases. Clin Vaccine Immunol (2006) 0.75
Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet (2009) 15.31
A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med (2003) 7.39
Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet (2009) 4.81
Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol (2007) 4.44
Pneumococcal vaccination for Indian children. Indian Pediatr (2007) 3.99
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol (2003) 3.27
Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA (2004) 2.90
The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines (2012) 2.79
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J (2003) 2.66
Development and use of the Lives Saved Tool (LiST): a model to estimate the impact of scaling up proven interventions on maternal, neonatal and child mortality. Int J Epidemiol (2010) 2.60
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med (2013) 2.54
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis (2010) 2.50
Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet (2003) 2.49
Pneumococcal vaccination in developing countries. Lancet (2006) 2.45
Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine (2009) 2.43
Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis (2005) 2.21
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med (2012) 2.17
The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin Infect Dis (2006) 2.12
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J (2006) 2.10
Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. J Infect Dis (2006) 2.10
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine (2007) 2.07
Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol (2006) 2.00
Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med (2005) 1.97
Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis (2004) 1.95
Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet (2009) 1.95
Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J (2006) 1.86
Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine (2007) 1.85
Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med (2013) 1.84
Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis (2009) 1.82
Improved detection of nasopharyngeal cocolonization by multiple pneumococcal serotypes by use of latex agglutination or molecular serotyping by microarray. J Clin Microbiol (2011) 1.82
Methodological and quality issues in epidemiological studies of acute lower respiratory infections in children in developing countries. Int J Epidemiol (2004) 1.72
Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J Infect Dis (2008) 1.72
Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics. Clin Infect Dis (2009) 1.70
Otitis media and its consequences: beyond the earache. Lancet Infect Dis (2010) 1.68
Global immunization: status, progress, challenges and future. BMC Int Health Hum Rights (2009) 1.67
Acute otitis media caused by Streptococcus pyogenes in children. Clin Infect Dis (2005) 1.64
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis (2007) 1.64
Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine (2007) 1.63
Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J (2004) 1.63
Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children. J Pediatr (2010) 1.61
Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis (2005) 1.61
Potential contribution by nontypable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J (2009) 1.60
Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res (2010) 1.60
Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol (2003) 1.53
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis (2006) 1.52
A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis (2009) 1.51
Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J (2006) 1.51
Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children. Pediatr Infect Dis J (2005) 1.49
Nasopharyngeal carriage of Streptococcus pneumoniae at the completion of successful antibiotic treatment of acute otitis media predisposes to early clinical recurrence. J Infect Dis (2005) 1.49
Validation of factor 6d antiserum for serotyping Streptococcus pneumoniae serotype 6C. J Clin Microbiol (2010) 1.48
Risk factors for human anthrax among contacts of anthrax-infected livestock in Kazakhstan. Am J Trop Med Hyg (2004) 1.48
Immunogenicity of pneumococcal conjugate vaccines in infants after two or three primary vaccinations: a systematic review and meta-analysis. Vaccine (2011) 1.48
A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS One (2012) 1.47
Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun (2002) 1.46
Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol (2013) 1.46
Cytology of middle ear fluid during acute otitis media. Pediatr Infect Dis J (2002) 1.45
Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ (2008) 1.44
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine (2008) 1.43
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine (2011) 1.43
Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of Streptococcus pneumoniae and Haemophilus influenzae from healthy and sick individuals varies with age. J Clin Microbiol (2004) 1.43
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis (2010) 1.39
Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol (2003) 1.38
Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis (2002) 1.38
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun (2003) 1.36
The future of immunisation policy, implementation, and financing. Lancet (2011) 1.36
Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine (2004) 1.35
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33
Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J (2005) 1.31
What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? J R Soc Interface (2009) 1.30
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
Effects of long-term storage on plasmid stability in Bacillus anthracis. Appl Environ Microbiol (2005) 1.30
Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol (2006) 1.30
Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines (2006) 1.29
Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis (2012) 1.29
High seroprevalence of human metapneumovirus among young children in Israel. J Infect Dis (2003) 1.29
The potential indirect effect of conjugate pneumococcal vaccines. Vaccine (2003) 1.28
Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J (2005) 1.28
Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis (2005) 1.27
A review of vaccine research and development: human acute respiratory infections. Vaccine (2005) 1.27
The expanded programme on immunization: a lasting legacy of smallpox eradication. Vaccine (2011) 1.26
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics (2009) 1.26
The "Achilles heel" of global efforts to combat infectious diseases. Clin Infect Dis (2006) 1.26
Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Clin Vaccine Immunol (2009) 1.25